Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 11/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 11/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | CDC42 | P60953 | 1/20 | 0.41 |
| ▸ | RAC1 | P63000 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24450952 | 0.88 | AKR1C3 (0.70) | AKR1C3AKR1C2TSHRLMNAMAPT | |
| SCHEMBL6369574 | 0.83 | AKR1C3 (0.77) | AKR1C3AKR1C2TSHRLMNACYP2C9 | |
| SCHEMBL680055 | 0.83 | AKR1C3 (0.77) | AKR1C3AKR1C2TSHRLMNACYP2C9 | |
| SCHEMBL14802250 | 0.80 | AKR1C3 (0.44) | AKR1C3AKR1C2TSHRLMNAMAPT | |
| SCHEMBL15449777 | 0.80 | AKR1C3 (0.44) | AKR1C3AKR1C2TSHRLMNAMAPT | |
| SCHEMBL11459991 | 0.79 | AKR1C3 (0.54) | AKR1C3AKR1C2TSHRLMNAMAPT | |
| SCHEMBL22217506 | 0.77 | PTGS2 (0.69) | AKR1C3AKR1C2TSHRLMNAMAPT | |
| SCHEMBL20887115 | 0.77 | PTGS2 (0.69) | AKR1C3AKR1C2TSHRLMNAMAPT | |
| SCHEMBL14817408 | 0.77 | PTGS2 (0.69) | AKR1C3AKR1C2TSHRLMNAMAPT | |
| SCHEMBL10309472 | 0.77 | AKR1C3 (0.49) | AKR1C3AKR1C2TSHRPTGS1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452220-B2 | Coupling compounds of NSAID anti-inflammatory and analgesic drugs and EGFR kinase inhibitors, synthesis methods and applications thereof | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2016-09-27 | — | — | US | disclosed |
| US-20160175453-A1 | COUPLING COMPOUNDS OF NSAID ANTI-INFLAMMATORY AND ANALGESIC DRUGS AND EGFR KINASE INHIBITORS, SYNTHESIS METHODS AND APPLICATIONS THEREOF | GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2016-06-23 | — | — | US | disclosed |
| US-20150148306-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | KANDULA MAHESH (IN) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175453-A1 | COUPLING COMPOUNDS OF NSAID ANTI-INFLAMMATORY AND ANALGESIC DRUGS AND EGFR KINASE INHIBITORS, SYNTHESIS METHODS AND APPLICATIONS THEREOF | EGFR, CHUK, ERBB2 | AKR1C3 1067/4885AKR1C2 1365/4885TSHR 3265/4885 |
| US-20150148306-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | IAPP, TTR, GPR119 | AKR1C3 400/4885AKR1C2 282/4885TSHR 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.